Varicella-zoster virus mRNA vaccine and application thereof

• Main Authors: GU ZHEN, MAO JUNSONG, LIU XIAOXI, LIU WEIWEI, GUO ZHIFENG, GAO CHENYANG, WANG LUFAN
• Format: Patent
• Language: Chinese; English
• Published: 16.08.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention provides a varicella-zoster virus mRNA (messenger Ribonucleic Acid) vaccine and application thereof. Point mutation and codon optimization are carried out on a CDS (Coding Sequence) in an mRNA nucleic acid sequence; a proper promoter, 5 '-UTR, 3'-UTR and 3 '-terminal PolyA are selected to be combined into complete mRNA nucleic acid for coding the varicella-zoster virus, the reagent formula of the mRNA vaccine is improved, the LNP drug loading capacity is improved, and finally, a strong and stable immune effect can be achieved, the antibody titer in an animal body is greatly improved, and the immune effect of the varicella-zoster virus is improved. And the varicella-zoster virus mRNA vaccine does not influence the normal growth of animals, the vaccine cost can be remarkably reduced, and the clinical application prospect is wide. 本发明提供了一种水痘-带状疱疹病毒mRNA疫苗及其应用，通过对mRNA核酸序列中的CDS序列进行点突变和密码子优化，再选择合适的启动子、5'-UTR、3'-UTR和3'-端PolyA组合成完整的编码水痘-带状疱疹病毒的mRNA核酸，并改进mRNA疫苗的试剂配方，提高LNP载药量，最终获得能呈现强烈且稳定的免疫效果，大幅提升动物体内的抗体滴